Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Condition:   Pathologic Residual Cancer Cells Interventions:   Drug: Capecitabine, Oral, 500 Mg;   Drug: Vinorelbine Tartrate Oral Sponsor:   Zhiyong Yu Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials